Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Completed · Phase 3 · Has a placebo group

Conditions studied: Compensated Cirrhosis, Nonalcoholic Steatohepatitis

In brief

The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

Key facts

Study ID
NCT03439254
Run by
Intercept Pharmaceuticals
People needed
919
Starts
2017-08-30
Expected to finish
2022-09-08
Last updated by the study team
2023-10-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.